Detailansicht

Wissensnetz

Person

Herta Wolf (1954-)

Kunsthistorikerin

Name	Herta Wolf
Zeit	1954- (Lebensdaten)
Ort	Graz (Geburtsort) Österreich
Geschlecht	weiblich
Akademischer Grad bzw. Titel	Professorin
Beruf	Kunsthistorikerin (charakteristischer Beruf)
Beziehung	Universität Duisburg-Essen (1994-2010) Universität zu Köln (2010-)
Themengebiet	Personen zu Kunstwissenschaft, Kunsthistoriker
Weitere Angaben	Prof. für Theorie und Geschichte der Fotografie
Quelle	Fotogeschichte 160/2021. - S. 80 Wikipedia: https://de.wikipedia.org/wiki/Herta_Wolf (Stand: 19.07.2024)
Datensatztyp	Person
GND-Nummer	120602555
Datensatz-ID	120602555
Beteiligt an alle anzeigen Schriften zur Photographie : Herausgegeben und kommentiert von Herta Wolf. Aus dem Englischen von Wilfried Prantner. Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological Studies Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^{177}\)Lu]Lu-PSMA I&T during long-term follow-up CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors — a comprehensive analysis of imaging findings and comparison with histopathology CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection CXCR4-targeted theranostics in oncology Matched-pair analysis of [\(^{177}\)Lu]Lu-PSMA I&T and [\(^{177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease Questionable value of of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging Red Bull PET/CT [18F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging PET-Derived Increased Inflammation in Large Vessels is linked to Relapse-Free Survival in Patients with Giant Cell Arteritis Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on \(^{18}\)F-DCFPyL PET/CT scans C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^{177}\)Lu]Lu-PSMA I&T Identitätskonstruktionen und Repräsentation in den fotografischen und filmischen Portraits von Friedl Kubelka und Lisl Ponger – Zur Genese der Selbst- und Fremdwahrnehmung In-vivo somatostatin-receptor expression in small cell lung cancer as a prognostic image biomarker and therapeutic target Interobserver agreement rates on C-X-C Motif chemokine receptor 4–directed molecular imaging and therapy Lack of repeatability of radiomic features derived from PET scans: results from a 18F‐DCFPyL test–retest cohort Predicting microenvironment in CXCR4- and FAP-positive solid tumors - a pan-cancer machine learning workflow for theranostic target structures Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer Vector autoregression: useful in rare diseases? — Predicting organ response patterns in a rare case of secondary AA amyloidosis Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma Generative adversarial network-created brain SPECTs of cerebral ischemia are indistinguishable to scans from real patients Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an (18F) FDG PET/CT in Patients with Giant Cell Arteritis CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma CXCR4-targeted theranostics in oncology Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens Diagnostic performance of IQ·SPECT with high-speed scanning: A preliminary quality control study in obese patients Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers (18F) DCFPyL PET/CT for Imaging of Prostate Cancer Theranostics bei gut bis mäßig differenzierten GEP-NEN

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Herta Wolf (1954-)

Schriften zur Photographie : Herausgegeben und kommentiert von Herta Wolf. Aus dem Englischen von Wilfried Prantner.

Prognostic role of quantitative [18F]FDG PET/CT parameters in adrenocortical carcinoma

Volumetric Parameters Derived from CXCR4-Directed PET/CT Predict Outcome in Patients with Gastrointestinal Neuroendocrine Carcinomas

Evaluating the Patterns of FAPI Uptake in the Shoulder Joint: a Preliminary Study Comparing with FDG Uptake in Oncological Studies

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [\(^{177}\)Lu]Lu-PSMA I&T during long-term follow-up

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors — a comprehensive analysis of imaging findings and comparison with histopathology

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection

CXCR4-targeted theranostics in oncology

Matched-pair analysis of [\(^{177}\)Lu]Lu-PSMA I&T and [\(^{177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease

Questionable value of of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging

Red Bull PET/CT

[18F]FDG PET/CT can trigger relevant oncological management changes leading to favorable outcome in iodine-negative thyroid cancer patients

CXCR4-directed PET/CT with [68 Ga]Ga-pentixafor in solid tumors—a comprehensive analysis of imaging findings and comparison with histopathology

Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG

Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy

Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging

SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors

Multi-timepoint imaging with PSMA-targeted [18F]F-Florastamin PET/CT: lesion detection and comparison to conventional imaging

PET-Derived Increased Inflammation in Large Vessels is linked to Relapse-Free Survival in Patients with Giant Cell Arteritis

Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy

Association of true positivity with serum prostate-specific antigen levels and other clinical factors in indeterminate PSMA-RADS-3A lesions identified on \(^{18}\)F-DCFPyL PET/CT scans

C-X-C motif chemokine receptor 4-targeted radioligand therapy in patients with advanced T-cell lymphoma

Chemokine receptor–targeted PET/CT provides superior diagnostic performance in newly diagnosed marginal zone lymphoma patients: a head-to-head comparison with [18F]FDG

Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy

CXCR4-directed imaging and endoradiotherapy in desmoplastic small round cell tumors

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^{177}\)Lu]Lu-PSMA I&T

Identitätskonstruktionen und Repräsentation in den fotografischen und filmischen Portraits von Friedl Kubelka und Lisl Ponger – Zur Genese der Selbst- und Fremdwahrnehmung

In-vivo somatostatin-receptor expression in small cell lung cancer as a prognostic image biomarker and therapeutic target

Interobserver agreement rates on C-X-C Motif chemokine receptor 4–directed molecular imaging and therapy

Lack of repeatability of radiomic features derived from PET scans: results from a 18F‐DCFPyL test–retest cohort

Predicting microenvironment in CXCR4- and FAP-positive solid tumors - a pan-cancer machine learning workflow for theranostic target structures

Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter

Rationalizing the binding modes of PET radiotracers targeting the norepinephrine transporter

Test-retest repeatability of organ uptake on PSMA‐targeted 18F‐DCFPyL PET/CT in patients with prostate cancer

Vector autoregression: useful in rare diseases? — Predicting organ response patterns in a rare case of secondary AA amyloidosis

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma

Generative adversarial network-created brain SPECTs of cerebral ischemia are indistinguishable to scans from real patients

Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy

Clinical Utility of C-Reactive Protein and White Blood Cell Count for Scheduling an (18F) FDG PET/CT in Patients with Giant Cell Arteritis

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection

Questionable value of [99mTc]-sestamibi scintigraphy in patients with pHPT and negative ultrasound

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma

CXCR4-targeted theranostics in oncology

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up

Diverse PSMA expression in primary prostate cancer: reason for negative [68Ga]Ga-PSMA PET/CT scans? Immunohistochemical validation in 40 surgical specimens

Diagnostic performance of IQ·SPECT with high-speed scanning: A preliminary quality control study in obese patients

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [68Ga]Ga-PentixaFor PET/CT

Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers

(18F) DCFPyL PET/CT for Imaging of Prostate Cancer

Theranostics bei gut bis mäßig differenzierten GEP-NEN